Drug intelligence / Profile preview

MTC-Ins

Development stage: Unknown
Lead developer: Biotts
Modality: Peptides
Administration: Transdermal

Overview

MTC-Ins is a transdermal insulin delivery system developed by Biotts for the treatment of diabetes mellitus. The product utilizes the proprietary Multilayer Transdermal Carrier (MTC) technology, which facilitates the non-invasive transport of large therapeutic molecules, such as insulin, through the skin and into the systemic circulation. By replacing traditional subcutaneous injections with a transdermal patch, MTC-Ins is designed to improve patient adherence and provide a more stable pharmacokinetic profile. The candidate is currently undergoing Phase 1 clinical trials to evaluate its safety, tolerability, and glucose-lowering efficacy.

Other names: insulin transdermal patchBiotts insulin patch

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on MTC-Ins.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MTC-Ins.

Explore the full profile